AR128113A1 - Composiciones que contienen fexofenadina - Google Patents

Composiciones que contienen fexofenadina

Info

Publication number
AR128113A1
AR128113A1 ARP220103594A ARP220103594A AR128113A1 AR 128113 A1 AR128113 A1 AR 128113A1 AR P220103594 A ARP220103594 A AR P220103594A AR P220103594 A ARP220103594 A AR P220103594A AR 128113 A1 AR128113 A1 AR 128113A1
Authority
AR
Argentina
Prior art keywords
fexofenadine
compositions containing
zwitterion
dihydrate
containing fexofenadine
Prior art date
Application number
ARP220103594A
Other languages
English (en)
Spanish (es)
Inventor
Daniela Maldonado Cavalari
Maxime Liboureau
Chakib Zaghloul
Original Assignee
Opella Healthcare Group Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opella Healthcare Group Sas filed Critical Opella Healthcare Group Sas
Publication of AR128113A1 publication Critical patent/AR128113A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP220103594A 2021-12-29 2022-12-27 Composiciones que contienen fexofenadina AR128113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/000916 WO2023126637A1 (en) 2021-12-29 2021-12-29 Compositions containing fexofenadine

Publications (1)

Publication Number Publication Date
AR128113A1 true AR128113A1 (es) 2024-03-27

Family

ID=80122351

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103594A AR128113A1 (es) 2021-12-29 2022-12-27 Composiciones que contienen fexofenadina

Country Status (13)

Country Link
US (1) US20250082623A1 (cg-RX-API-DMAC10.html)
EP (1) EP4456880B1 (cg-RX-API-DMAC10.html)
JP (1) JP7826492B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240136358A (cg-RX-API-DMAC10.html)
CN (1) CN118715004A (cg-RX-API-DMAC10.html)
AR (1) AR128113A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021480621A1 (cg-RX-API-DMAC10.html)
CA (1) CA3242293A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024009774A2 (cg-RX-API-DMAC10.html)
ES (1) ES3069308T3 (cg-RX-API-DMAC10.html)
MX (1) MX2024008242A (cg-RX-API-DMAC10.html)
PE (1) PE20242355A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023126637A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
FR2959130A1 (fr) 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
CN102512389B (zh) 2011-12-27 2013-08-21 天津市嵩锐医药科技有限公司 非索非那定盐酸盐口腔崩解药物组合物
KR101761983B1 (ko) * 2014-08-25 2017-08-07 아주대학교산학협력단 구강내 속붕해 필름 조성물 및 그 제조방법
CN105997910A (zh) 2016-06-09 2016-10-12 北京化工大学 一种掩味制剂及其制备方法

Also Published As

Publication number Publication date
US20250082623A1 (en) 2025-03-13
AU2021480621A1 (en) 2024-07-18
EP4456880A1 (en) 2024-11-06
ES3069308T3 (en) 2026-06-05
PE20242355A1 (es) 2024-12-16
MX2024008242A (es) 2024-07-19
EP4456880B1 (en) 2026-03-18
JP7826492B2 (ja) 2026-03-09
KR20240136358A (ko) 2024-09-13
JP2024546513A (ja) 2024-12-24
EP4456880C0 (en) 2026-03-18
CA3242293A1 (en) 2023-07-06
WO2023126637A1 (en) 2023-07-06
CO2024009774A2 (es) 2024-08-08
CN118715004A (zh) 2024-09-27

Similar Documents

Publication Publication Date Title
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
CO2021005711A2 (es) Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
CL2022002695A1 (es) Inhibidores de rip1k
MX2020011868A (es) Inhibidores de los receptores erbb.
CO2024012792A2 (es) Compuestos como agonistas de glp-1r
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
PE20241305A1 (es) Analogos de amilina
DOP2022000042A (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
CL2021002447A1 (es) (divisional de solicitud 2218-2019) formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2021001956A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables. (divisional solicitud 202002624)
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
AR107391A1 (es) Formulaciones / composiciones que comprenden un inhibidor de btk
MX2018005786A (es) Formulaciones novedosas.
MX2023002450A (es) Formulaciones farmaceuticas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico o la adenomiosis.
WO2019073331A3 (en) Pharmaceutical compositions of apremilast
PY1929301A (es) Formulación sólida de mezclas insecticidas.-
AR045193A1 (es) Composicion de fexofenadina y proceso de preparacion
BR112022007207A2 (pt) Composição farmacêutica que compreende selexipag
CL2022003812A1 (es) Inhibidores de rip1k
CO5280222A1 (es) Composicion farmaceutica que comprende pemetrexed
HN2012001923A (es) Hidrato del hidrocloruro de agomelatina y preparacopn de este
PE20060160A1 (es) Formulaciones de tableta recubierta que comprenden peliglitazar o muraglitazar y procedimiento
CL2009000636A1 (es) Compuestos derivados de 1-(1h-pirazol-3-il)-imidazolidin-4-ona sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de enfermedades retrovirales, tal como infeccion por vih.
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3